Mark D’Amico
- Molecular Biology top 2%
- Cancer-related gene regulation 4
- Cell death mechanisms and regulation 3
- RNA modifications and cancer 2
- Epigenetics and DNA Methylation 2
- Mechanisms of cancer metastasis 1
- Oncology top 2%
- Cancer-related Molecular Pathways 9
- Cancer Research top 5%
- NF-κB Signaling Pathways 2
- Cell Biology top 5%
-
- Virus-based gene therapy research 1
- Co-authors
- Richard G. PestellChris AlbaneseAvri Ben‐Ze'evInbal SimchaMichael ShtutmanJacob ZhurinskyMaofu FuRichard J. Lee
- Journals
- Journal of Biological Chemistry (3 papers)Molecular Biology of the Cell (1 paper)Nature Genetics (1 paper)
- Partner nations
- United StatesIsraelSouth Korea
In The Last Decade
Mark D’Amico
15 papers receiving 3.3k citations
Hit Papers
Peers
Comparison fields: 5 of 107
- Molecular Biology 2.7k
- Oncology 1.0k
- Cancer Research 461
- Cell Biology 352
- Pathology and Forensic Medicine 234
Countries citing papers authored by Mark D’Amico
This map shows the geographic impact of Mark D’Amico's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark D’Amico with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark D’Amico more than expected).
Fields of papers citing papers by Mark D’Amico
This network shows the impact of papers produced by Mark D’Amico. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark D’Amico. The network helps show where Mark D’Amico may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Mark D’Amico, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2008 | 17 | |
| 2 | 2007 | 18 | |
| 3 | 2005 | 4 | |
| 4 | 2004 | 33 | |
| 5 | 2003 | 131 | |
| 6 | 2003 | 107 | |
| 7 | 2003 | 189 | |
| 8 | The role of Ink4a/Arf in ErbB2 mammary gland tumorigenesis. | 2003 | 25 |
| 9 | Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells: association with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways. | 2002 | 52 |
| 10 | 2000 | 305 | |
| 11 | 2000 | 48 | |
| 12 | 1999 | 160 | |
| 13 | 1999 | 253 | |
| 14 | The cyclin D1 gene is a target of the β-catenin/LEF-1 pathwaybreakdown → | 1999 | 1913 |
| 15 | 1999 | 48 |
About Mark D’Amico
Mark D’Amico is a scholar working on Oncology, Cancer Research, Molecular Biology, Reproductive Medicine and Biotechnology, having authored 15 papers that have together received 3.3k indexed citations. Recurring topics across this work include Cancer-related Molecular Pathways (9 papers), Cancer-related gene regulation (4 papers), Cell death mechanisms and regulation (3 papers), RNA modifications and cancer (2 papers), Epigenetics and DNA Methylation (2 papers), NF-κB Signaling Pathways (2 papers), Mechanisms of cancer metastasis (1 paper) and Virus-based gene therapy research (1 paper). The work is most often cited by research in Molecular Biology (2.7k citations), Oncology (1.0k citations), Cancer Research (461 citations), Cell Biology (352 citations) and Pathology and Forensic Medicine (234 citations). Mark D’Amico has collaborated with scholars based in United States, Israel and South Korea. Frequent co-authors include Richard G. Pestell, Chris Albanese, Avri Ben‐Ze'ev, Inbal Simcha, Michael Shtutman, Jacob Zhurinsky, Maofu Fu, Richard J. Lee, Genichi Watanabe and Kongming Wu. Their work appears in journals such as Journal of Biological Chemistry, Molecular Biology of the Cell, Nature Genetics, Investigational New Drugs and Cell Cycle.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.